Lacking A Clear Disease Setting, Sanofi’s Semuloparin Fails ODAC Vote
Executive Summary
It isn’t clear to either FDA or the Oncologic Drugs Advisory Committee what specific cancer chemotherapy setting would be the most useful for Sanofi-Aventis’ semuloparin, a low molecular weight heparin intended to prevent venous thromboembolism.